News

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks.
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...
Hims & Hers Health ( ($HIMS) ) has risen by 21.11%. Read on to learn why. Hims & Hers Health has experienced a notable 21.11% ...
Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and safety concerns.
Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...
We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...
Executives and directors of Hims & Hers Health Inc., a leading telehealth company, are facing a shareholder derivative ...
Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...